

CURRICULUM VITAE

NAME Sung-Soo Park, MD (Date of Birth : March 2, 1983)
Office Address Seoul St. Mary's Hospital
222 Banpo-daero, Seocho-gu, Seoul 06591, South Korea
Phone: +82-2-2258-6754
Fax: +82-2-599-3589
e-mail: sspark@catholic.ac.kr

ACADEMIC RANK & POSITION

18. February, 2008	Acquisition of medical (doctoral) license (No. 95674)
March 2008 – February 2009	Internship
March 2009 – April 2012	Navy Doctor, Lieutenant, Republic of Korean Navy
May 2012 – February 2016	Resident of internal medicine, Catholic medical center, The Catholic Univ. of Korea
March 2016 – February 2018	Fellow, Division of Hematology, Department of Internal Medicine, Seoul St Mary's hospital, College of Medicine, The Catholic university of Korea
March 2018 – February 2023	Assistant professor, Division of Hematology, Seoul St Mary's hematology hospital, College of Medicine, The Catholic university of Korea
March 2023 –	Associate professor, Division of Hematology, Seoul St Mary's hematology hospital, College of Medicine, The Catholic university of Korea

EDUCATION

February, 2008	Achievement of Bachelor degree The Catholic university of Korea, Seoul, Korea
August, 2017	Achievement of Master's degree The Catholic university of Korea, Seoul, Korea
August, 2020	Achievement of Doctor's degree The Catholic university of Korea, Seoul, Korea

GCP training

April 2016	GCP training, Seoul St. Mary's Hospital, Certificate Number : CRCC-CTI-CMC-16013654
November 2017	GCP training, Seoul St. Mary's Hospital, Certificate Number: CTI-GCP-SSMH-17014279
September 2018	GCP training, Seoul St. Mary's Hospital, Certificate Number: CTI-CNT-SSMH-18014182
June 2019	GCP training, Seoul St. Mary's Hospital, Certificate Number: CTI-CNT-SSMH-19013086
April 2020	GCP training, Seoul St. Mary's Hospital, Certificate Number: HRPP-GCP-CMC-20012180
July 2021	GCP training, Seoul St. Mary's Hospital, Certificate Number: HRPP-GCP-CMC-21015653
August 2022	GCP training, Seoul St. Mary's Hospital, Certificate Number: HRPP-GCP-CMC-22028388

AWARDS

1. Poster presentation award from Korean Society of Blood and Marrow Transplantation, 2016
2. Oral presentation award from Korean Society of Hematology, 2017
3. Academic Award from Catholic University of Korea, Graduate School, 2017
4. Poster presentation award from Korean society of Hematology, 2019
5. Academic Award from Catholic University of Korea, Graduate School, 2020
6. Poster presentation award from International Congress of BMT 2021
7. Distinguished Investigator Award from Korean Society of Hematology, 2022
8. Oral presentation award from Korean Society of Blood and Marrow Transplantation, 2022
9. Poster presentation award from Annual Meeting of the Japanese Society of Myeloma, 2023
10. Yoo Seon-hee Teresa Award from Catholic University of Korea, 2023

BOARD CERTIFICATION

1. Board certified in specialty of Internal Medicine, March. 2016, Certificate # 15964, Korea

MEMBERSHIP IN PROFESSIONAL SOCIETIES

1. Korean Society of Hematology
2. Korean Society of Hematopoietic Stem Cell Transplantation

3. Korean Society of Internal Medicine
4. International Society For Cell & Gene therapy

NATIONAL RESEARCH GRANT (Responsible researcher only)

1. Development of large-scale NGS data-based diagnostic test for hematologic malignancies : Supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2018M3A9E8020866).
2. Acquirement of original specimen for organoid generation and establishment of advanced regenerative clinical research plan (2021-HH21C0018)
3. A study for the establishment of evidence for the development of an optimal decision-making tool based on circulating cell-free DNA for Multiple Myeloma (2021R1G1A1093870)
4. Efficacy and safety evaluation study of advanced immunotherapeutic agents based on RWD of hematologic malignancy (RS-2023-00216446)

PATENT APPLICATION

1. Method of providing the information for predicting of hematologic malignancy prognosis after peripheral blood stem cell transplantation [number: 10-2019-0117369] and [number: PCT/KR2019/016556]
2. Oral cooler using cooling balloon [number: 10-2019-0136648]
3. APPARATUS, METHOD AND RECORDING MEDIUM FOR PROGNOSTIC PREDICTION [number: 10-2021-0110005]
4. METHOD, DEVICE AND STORAGE MEDIUM RECORDING PROGRAM FOR PROVIDING NECESSARY INFORMATION FOR SELECTING TREATMENT OPTION [number, 10-2023-0065607]

RESEARCH PUBLICATIONS ([co-]First or [co-]Corresponding author only)

1. Park SS, Kim SH, Kim M, et al. A Case of Severe Pseudomembranous Tracheobronchitis Complicated by Co-infection of Influenza A (H1N1) and Staphylococcus aureus in an Immunocompetent Patient. *Tuberc Respir Dis (Seoul)*. 2015;78:366-370.
2. Park SS, Lee SE, Min CK. Emphysematous osteomyelitis due to Escherichia coli in multiple myeloma. *Blood Res*. 2016;51:224.
3. Park SS, Kwak DH, Jeon YW, et al. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. *Biol Blood Marrow Transplant*. 2017;23:1498-1508.
4. Park SS, Yoon JH, Kim HJ, et al. Characteristics and Survival Outcome Analysis of Extramedullary Involvement in Adult Patients With t(8;21) Acute Myeloid Leukemia. *Clin Lymphoma Myeloma*

Leuk. 2017;17:38-45.e32.5.

5. Park SS, Kim HJ, Min KI, et al. Prognostic Prediction Model for Second Allogeneic Stem-Cell Transplantation in Patients With Relapsed Acute Myeloid Leukemia: Single-Center Report. *Clin Lymphoma Myeloma Leuk.* 2018;18:e167-e182.

6. Park SS, Eom HS, Kim JS, et al. Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. *Jpn J Clin Oncol.* 2019;49:92-95.

7. Park SS, Jeon YW, Min GJ, et al. Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome. *Biol Blood Marrow Transplant.* 2019;25:63-72.

8. Park SS, Kim K, Kim SJ, Lee JH, Yoon SS, Mun YC et al. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. *Biol Blood Marrow Transplant* 2019; 25: 1312-1319.

9. Park SS, Cho SY, Han E, Min GJ, Park S, Yoon JH et al. Reactivation and dynamics of cytomegalovirus and Epstein-Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia. *Eur J Haematol* 2019; 103: 433-441.

10. Park SS, Min GJ, Park S, Lee SE, Yoon JH, Cho BS, et al. Excellent outcomes of hematopoietic stem cell transplantation with total nodal irradiation and antithymocyte globulin conditioning in severe aplastic anemia with advanced age and/or severe comorbidity. *Bone Marrow Transplant.* 2020;55(7):1447-50.

11. Park SS, Lim JY, Kim TW, Ko YH, Jeon WJ, Lee SY et al. Predictive impact of circulating microRNA-193a-5p on early relapse after autologous stem cell transplantation in patients with multiple myeloma. *Br J Haematol.* 2020; 189: 518–523

12. Cho SY, Park SS, Lee JY, Kim HJ, Kim YJ, Min CK, et al. Successful prevention and screening strategies for COVID-19: focus on patients with haematologic diseases. *British journal of haematology.* 2020;190(1):e33-e7.

13. Ha J, Park SS, Park S, Yoon JH, Baek KH, Kim HJ, et al. Effects of Hormone Replacement Therapy on Bone Mass After Allogeneic Hematopoietic Stem Cell Transplantation. *J Clin Endocrinol Metab.* 2020;105(9).

14. Wang SM, Park SS, Park SH, Kim NY, Kang DW, Na HR, et al. Pre-transplant depression decreased overall survival of patients receiving allogeneic hematopoietic stem cell transplantation: a nationwide cohort study. *Sci Rep.* 2020;10(1):15265.

15. Cho SY, Park SS, Song MK, Bae YY, Lee DG, Kim DW. Prognosis Score System to Predict Survival for COVID-19 Cases: a Korean Nationwide Cohort Study. *J Med Internet Res.*

2021;23(2):e26257.

16. Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. *Cancers (Basel)*. 2021;13(3).
17. Park SS, Min Byun J, Yoon SS, Kim K, Jung SH, Lee JJ, et al. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy. *British journal of haematology*. 2021;193(1):101-12.
18. Wang SM, Park SS, Park SH, Kim NY, Kang DW, Na HR, et al. Pre-transplant Dementia is Associated with Poor Survival After Hematopoietic Stem Cell Transplantation: A Nationwide Cohort Study with Propensity Score Matched Control. *Clin Psychopharmacol Neurosci*. 2021;19(2):294-302.
19. Wang SM, Park SH, Kim NY, Kang DW, Na HR, Um YH, et al. Association between Dementia and Clinical Outcome after COVID-19: A Nationwide Cohort Study with Propensity Score Matched Control in South Korea. *Psychiatry Investig*. 2021;18(6):523-9
20. Park SS, Kim HJ, Kim TY, Lee JY, Lee JH, Min GJ, et al. Development and validation of a comorbidity index for predicting survival outcomes after allogeneic stem cell transplantation in adult patients with acute leukemia: a Korean nationwide cohort study. *Blood research*. 2021;56(3):184-96.
21. Ha J, Park SH, Park SS, Han S. Metabolic Disease Incidence After Allogeneic Stem Cell Transplantation: A Nationwide Korean Case-Control Study. *J Clin Endocrinol Metab*. 2022;107(4):943-52.
22. Kim JH, Park SS, Yoon JH, Lee SE, Kim HJ, Min CK. Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second. *Blood research*. 2022;57(1):76-80.
23. Kim SY, Park SS, Lim JY, Lee JY, Yoon JH, Lee SE, et al. Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone. *Exp Hematol*. 2022;110:60-8.
24. Park SS, Park SH, Han S. Risk of secondary nonhematologic malignancies after allogeneic stem cell transplantation: A nationwide case-control cohort study. *Int J Cancer*. 2022 Oct 1;151(7):1024-1032.
25. Jung SH, Park SS, Lim JY, et al. Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness. *Exp Mol Med*. 2022;54(11):1967-1978.
26. Kim Y, Park SS, Jeon YW, et al. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study. *Transplant Cell Ther*. 2023;29(1):55.e1-55.e9.
27. Byun JM, Park SS, Yoon SS, et al. Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study [published online ahead of print, 2023 Apr 7]. *Blood Res*. 2023;10.5045/br.2023.2023005.
28. Park SS, Lee JC, Byun JM, et al. ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma. *NPJ Precis Oncol*. 2023;7(1):46.